Moomoo AI 已提取核心訊息
On December 31, 2023, Altimmune, Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing, dated February 14, 2024, reports that Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, have updated their holdings in Altimmune's common stock. NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares. Collectively, these holdings represent a total of 3.21% of the company's common stock. The filing specifies that these shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers.
On December 31, 2023, Altimmune, Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing, dated February 14, 2024, reports that Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, have updated their holdings in Altimmune's common stock. NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares. Collectively, these holdings represent a total of 3.21% of the company's common stock. The filing specifies that these shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers.
2023年12月31日，生物製藥公司Altimmune, Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，這表明重要投資者的所有權發生了變化。這份日期爲2024年2月14日的文件報告稱，總部位於特拉華州的Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL）已經更新了其在Altimmune普通股中的持有量。不結盟運動報告了6,679股股票的所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股股票。這些持股總共佔公司普通股的3.21％。該文件指出，這些股份是在正常業務過程中收購的，無意改變或影響Altimmune的控制權。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些機構投資經理。
2023年12月31日，生物製藥公司Altimmune, Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，這表明重要投資者的所有權發生了變化。這份日期爲2024年2月14日的文件報告稱，總部位於特拉華州的Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL）已經更新了其在Altimmune普通股中的持有量。不結盟運動報告了6,679股股票的所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股股票。這些持股總共佔公司普通股的3.21％。該文件指出，這些股份是在正常業務過程中收購的，無意改變或影響Altimmune的控制權。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些機構投資經理。
有用
沒用